GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Brain+ AS (OCSE:BRAINP) » Definitions » Institutional Ownership

Brain+ AS (OCSE:BRAINP) Institutional Ownership : 0.00% (As of Mar. 25, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Brain+ AS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Brain+ AS's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Brain+ AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Brain+ AS's Float Percentage Of Total Shares Outstanding is 0.00%.


Brain+ AS Institutional Ownership Historical Data

The historical data trend for Brain+ AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brain+ AS Institutional Ownership Chart

Brain+ AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Institutional Ownership
- - - - -

Brain+ AS Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Institutional Ownership Get a 7-Day Free Trial Premium Member Only - - - - -

Brain+ AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Brain+ AS Business Description

Traded in Other Exchanges
N/A
Address
Kobmagergade 53, 3rd Floor, Copenhagen, DNK, 1150
Brain+ AS is a digital therapeutics company. It restores patients' quality of life by treating and detecting a cognitive decline in Alzheimer's disease and dementia through digital means. It has developed a set of Digital Medicine technologies. Its product pipeline includes CST Therapist Companion, and CST Home Companion; CST Home Care; CST for Mild Cognitive Impairment (MCI).

Brain+ AS Headlines

No Headlines